Sponsor
Peking University People's Hospital
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Peking University People's Hospital appears in 151 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownEfficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisNCT07796516 · lead sponsor · 2026-09-01
RECRUITINGReal-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerNCT07600164 · lead sponsor · 2026-07-06
RECRUITINGClinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung DiseaseNCT07843381 · lead sponsor · 2026-05-01
RECRUITINGCDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant TreatmentNCT07366112 · lead sponsor · 2026-04-20
RECRUITINGCadherin 3(CDH3)-Targeted PET in Lung Malignant TumorsNCT07487883 · lead sponsor · 2026-03-18
RECRUITINGA Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer PatientsNCT07238894 · lead sponsor · 2026-03-03
RECRUITINGFucoidan in the Treatment of Active Rheumatoid ArthritisNCT07045896 · lead sponsor · 2026-01-10
RECRUITINGAblation Compare With Surgery for Early Breast CancerNCT07484087 · lead sponsor · 2026-01-01
RECRUITINGRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsNCT07586826 · lead sponsor · 2025-12-22
RECRUITINGctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerNCT06970912 · lead sponsor · 2025-08-01
RECRUITINGMechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung CancerNCT07359040 · lead sponsor · 2025-07-01
RECRUITINGFAP-targeted PET/NIR in Lung Malignant TumorsNCT07498933 · lead sponsor · 2025-06-03
RECRUITINGTo Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)NCT07291921 · lead sponsor · 2025-05-08
RECRUITINGLiquid Biopsy-Based Novel Modality for Postoperative Management of Lung CancerNCT06930807 · lead sponsor · 2025-03-25
RECRUITINGKahook Dual Blade Goniotomy in Chronic Primary Angle-Closure GlaucomaNCT07517302 · lead sponsor · 2025-03-01
RECRUITINGVitreous Zonule in Primary Angle-Closure GlaucomaNCT07523139 · lead sponsor · 2025-01-01
RECRUITINGBCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesNCT06794008 · lead sponsor · 2024-12-26
RECRUITINGImpact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor SurgeryNCT06725082 · lead sponsor · 2024-12-01
RECRUITINGA RWS of SC MTX in Chinese RA PatientsNCT07463937 · lead sponsor · 2024-09-03
RECRUITINGClinical Study of a New Treatment Model for Elderly Lung Cancer PatientsNCT07632664 · lead sponsor · 2024-08-01
RECRUITINGFluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyNCT05576389 · lead sponsor · 2022-10-01
RECRUITINGThe Beijing Angle Closure Progression StudyNCT05563623 · lead sponsor · 2022-08-04
RECRUITINGMultiomics Tumor Evolution Model of NSCLCNCT05352035 · lead sponsor · 2022-04-20
RECRUITINGNeoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer PatientsNCT04836156 · lead sponsor · 2021-04-02
RECRUITINGNeoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer PatientsNCT04750122 · lead sponsor · 2021-03-28
RECRUITINGDe-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBCNCT06692725 · lead sponsor · 2019-01-01
RECRUITINGADC Based Therapy Accroding to HER2 HeterogeneousNCT07844018 · lead sponsor · 2027-01-01
NOT_YET_RECRUITINGA Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast CancerNCT07844291 · lead sponsor · 2026-11-01
NOT_YET_RECRUITINGStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNCT07849348 · lead sponsor · 2026-09-01
NOT_YET_RECRUITINGPreliminary Evaluation of a Large Language Model-Based Tool for Complex Surgical Decision Support in Lung CancerNCT07654036 · lead sponsor · 2026-06-10
COMPLETEDNon-Contrast Breast MRI Diagnosis and Risk Stratification Using DWI-Generated Synthetic Contrast EnhancementNCT07598084 · lead sponsor · 2026-06-01
NOT_YET_RECRUITINGDeep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CTNCT07647692 · lead sponsor · 2026-06-01
NOT_YET_RECRUITINGApplication of FreeStyle Libre 2 for Evaluating Glycemic Variability Characteristics in Patients With Extreme Glucose Metabolism PhenotypesNCT07564518 · lead sponsor · 2026-05-25
NOT_YET_RECRUITINGClinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced PainNCT07593365 · lead sponsor · 2026-05-06
NOT_YET_RECRUITINGPredicting the Risk of Partial Ciliary Block After Cataract and Goniosynechialysis Surgery in Primary Angle-Closure DiseaseNCT07549438 · lead sponsor · 2026-04-20
NOT_YET_RECRUITINGA Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast CancerNCT07294339 · lead sponsor · 2026-04-01
NOT_YET_RECRUITINGImpact of Perioperative Body Temperature on Postoperative Complications and Pain in Video-assisted Thoracoscopic Surgery Patients Utilizing Continuous Temperature MonitoringNCT07251439 · lead sponsor · 2026-01-01
NOT_YET_RECRUITINGA Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant ImmunotherapyNCT07119190 · lead sponsor · 2025-08-06
NOT_YET_RECRUITINGSpontaneous Breathing Mode: A Risk for Hypoxemia During OLV?NCT07494006 · lead sponsor · 2025-07-15
ENROLLING_BY_INVITATIONObservation and Study on the Application of Different Analgesic Regimens in Critically Ill Patients Without Mechanical VentilationNCT07031453 · lead sponsor · 2025-06-01
NOT_YET_RECRUITINGComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNCT07010588 · lead sponsor · 2025-06-01
NOT_YET_RECRUITINGTherapy of Niacin for Rheumatoid ArthritisNCT07004725 · lead sponsor · 2025-05-28
NOT_YET_RECRUITINGMass Spectrometry-based Immune Profiling in Autoimmune DiseasesNCT07188285 · lead sponsor · 2025-05-25
ENROLLING_BY_INVITATIONApplication-Assisted Weight Management in Endometrial Cancer Fertility PreservationNCT06901778 · lead sponsor · 2025-03-31
NOT_YET_RECRUITINGTreatment Duration of IPANCT06583512 · lead sponsor · 2024-12-01
ACTIVE_NOT_RECRUITINGLorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung CancerNCT06682884 · lead sponsor · 2024-11-15
NOT_YET_RECRUITINGProximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.NCT07335952 · lead sponsor · 2024-09-02
COMPLETEDThe Effects of Programmed Death-ligand 1 on Postoperative Pain for Lung Cancer PatientsNCT06503432 · lead sponsor · 2024-07-20
UNKNOWNEfficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection TherapyNCT06418464 · lead sponsor · 2024-07-01
UNKNOWNThe Effect of CPAP on Maternal and Infant Outcomes in Pregnant Women With OSASNCT06344702 · lead sponsor · 2024-05-01
UNKNOWNThe Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 DiabetesNCT06408532 · lead sponsor · 2024-04-30
UNKNOWNClinical Effect of Individualized Exercise Prescription for Hypertension With 6-minute Walking Test (6MWT)NCT06219512 · lead sponsor · 2024-02-01
NOT_YET_RECRUITINGA Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseNCT06134063 · lead sponsor · 2023-11-01
UNKNOWNEffect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial CancerNCT06312917 · lead sponsor · 2023-08-01
COMPLETEDNeoadjuvant Toripalimab for Non-squamous NSCLC With EGFR MutationNCT05962021 · lead sponsor · 2023-08-01
UNKNOWNSGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal InsufficiencyNCT05737186 · lead sponsor · 2023-03-09
TERMINATEDHbA1c Prediction Model in Patients With Type 2 DiabetesNCT05824286 · lead sponsor · 2023-01-04
UNKNOWNNeoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction AdenocarcinomaNCT05505461 · lead sponsor · 2023-01-01
NOT_YET_RECRUITINGPrevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase InhibitorsNCT05628077 · lead sponsor · 2022-12-30
UNKNOWNLow-dose Interleukin-2 and Rapamycin on sjögren's SyndromeNCT05605665 · lead sponsor · 2022-12-05
COMPLETEDSponsor roles
lead sponsor121
collaborator30
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.